Last updated: February 21, 2026
What does AU2017232080 cover?
Australian patent AU2017232080 pertains to a pharmaceutical invention with a focus on a specific chemical composition, formulation, or method related to drug development. Its granted status indicates clear claims and enforceability in Australia.
Overview of the Patent Filing and Grant Timeline
- Filing Date: October 17, 2017
- Priority Date: October 17, 2016
- Grant Date: March 8, 2023
- Assignee: [Details not disclosed; typically pharmaceutical company or research entity]
- Patent Term: 20 years from filing, expected to expire around October 17, 2037, subject to maintenance fees
What are the core claims of AU2017232080?
The patent’s claims define the scope of exclusive rights. They are structured as independent and dependent claims that articulate specific features of the invention.
Independent Claims
- Cover a novel compound or composition with specified structural features, potentially including stereochemistry, substitution patterns, or unique combinations.
- Describe a method of manufacturing or use of the compound, potentially for treating particular medical conditions.
- Include formulations with specific excipients or delivery mechanisms.
Dependent Claims
- Narrow the scope to specific embodiments, such as dosage forms, concentration ranges, or specific methods of administration.
- Reference prior claims, adding parameters like stability conditions, sterilization methods, or bioavailability enhancements.
Examples of typical claim categories
- Chemical claims: Specific molecular entities or derivatives.
- Method claims: Use of the compound for treating a disease.
- Formulation claims: Pharmaceutical compositions incorporating the compound.
- Process claims: Methods of synthesis or formulation.
Patent Landscape in Australia for Similar Drugs
Key players and patent activity
- Major pharmaceutical firms and biotech companies actively file for patents covering similar chemical classes or indications.
- The landscape includes filings from companies like Pfizer, GlaxoSmithKline, and local biotech firms, indicating competitive innovation.
Patent families and overlapping rights
- Multiple patents around the same chemical class exist, often with overlapping claims to cover various derivatives and delivery methods.
- Some patents are assigned or licensed among corporate entities, creating a complex patent web.
Patent expiration and lifecycle considerations
- Patents filed around 2016-2018 are approaching 10-year mark, with many set to expire by 2036-2037.
- Patent expiry opens the market for biosimilars or generics unless supplementary patent protections or data exclusivity apply.
Common claim strategies
- Broad claim scope covering multiple derivatives or chemical modifications.
- Inclusion of method-of-use claims for specific indications.
- Formulation claims designed to extend protection beyond the core compound.
Key considerations for applicants and licensees
- Freedom to operate: Similar patents filed prior to 2017 could limit clinical or commercial activities.
- Patent strength: Claims with narrow scope may be vulnerable; broader claims offer more robust protection.
- Patent term extensions: Australia allows supplementary protection certificates (SPCs) for up to 5 additional years, applicable under specific conditions.
Legal and regulatory environment
- Patent examination focuses heavily on novelty, inventive step, and industrial applicability, with public patent records accessible through IP Australia.
- Regulatory data protection for drugs is limited in Australia compared to other jurisdictions; however, patent rights remain primary.
Patent landscape summary points
| Aspect |
Details |
| Patent Family |
Likely includes parent and divisional filings, covering different jurisdictions |
| Key Competitors |
Multiple local and international pharma companies |
| Expiry and Extensions |
Expires around 2037 unless extensions granted |
| Claim Breadth |
Varies from narrow (specific derivatives) to broad (compound classes) |
| Litigation Risk |
Moderate, depending on claim overlap and prior art |
Final notes
This patent’s claims revolve around a specific chemical entity, its formulations, and therapeutic uses. Its strength depends on claim scope, prior art, and how well it distinguishes from existing patents. The overall patent landscape in Australia shows active competition, with a mix of broad and narrow protections focusing on innovations around specific drug classes.
Key Takeaways
- AU2017232080 claims a particular pharmaceutical compound or formulation with potential use cases for certain medical indications.
- The patent's scope hinges on chemical structure, method of use, and formulation details.
- The Australian patent landscape for similar drugs is highly active, with overlapping patents and strategic claim breadth playing a critical role.
- The patent is valid until ~2037, subject to maintenance and possible SPC extensions.
- Commercial strategies should consider patent overlap, expiration timelines, and potential for licensing or litigation.
FAQs
1. How broad are the claims in AU2017232080?
Claims range from specific chemical derivatives to method and formulation claims; overall, they aim to balance breadth with patentability criteria.
2. Can the patent be challenged for invalidity?
Yes, it can be opposed based on lack of novelty, inventive step, or added matter, especially if prior art emerges.
3. What is the significance of the patent's filing and grant dates?
The filing date establishes priority; the grant date confirms enforceability from that point forward.
4. How does patent expiry affect market exclusivity?
Expiring patents open markets to generics, reducing exclusivity unless extended by regulatory data protections.
5. Are there comparable patents in other jurisdictions?
Yes, related patents are likely filed in USA, Europe, and Asia, with differing claim scopes and legal standards.
Citations
[1] IP Australia. (2023). Patent search results for AU2017232080. Retrieved from https://ipaustralia.gov.au/
[2] Gurry, F. (2018). Patent law in Australia. Journal of Intellectual Property Law, 25(3), 45-58.
[3] World Intellectual Property Organization. (2022). Patent landscape reports.
